Avnish Shetty, Sr. Medical Content Writer

Heart Rate at Baseline Influences the Effect of Ivabradine on Cardiovascular Outcomes in Chronic Heart Failure: Analysis from the SHIFT Study

In SHIFT (Systolic heart failure treatment with the If inhibitor ivabradine trial), heart rate reduction with the If inhibitor ivabradine significantly reduced major cardiovascular outcomes in HF patients in sinus rhythm with heart rate ≥70 bpm.

Efficacy and Safety of Ivabradine in Japanese Patients with Chronic Heart Failure ― J-SHIFT Study ―

Increased heart rate (HR) is an independent risk factor for cardiovascular outcomes in chronic heart failure (HF).

Efficacy and Safety of Ivabradine in Patients with Chronic Systolic Heart Failure and Diabetes: An Analysis from the SHIFT Trial

Diabetes mellitus and chronic heart failure (HF), both common conditions increasing in prevalence as the general population ages, are significant burdens to public health.